# EDGAR Filing Document

**Accession Number:** 0000704440
**File Stem:** 0001161697-25-000246
**Filing Date:** 2025-8
**Character Count:** 7558
**Document Hash:** 021a570718aee3e3f2fa03a6784bceab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001161697-25-000246.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001161697-25-000246

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250512

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Adams Thomas Edward
- **CENTRAL INDEX KEY:** 0001939226

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39086
- **FILM NUMBER:** 251202349

**MAIL ADDRESS:**
- **STREET 1:** 524 WOODLAND AVENUE
- **CITY:** BRIELLE
- **STATE:** NJ
- **ZIP:** 08730
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KORU Medical Systems, Inc.
- **CENTRAL INDEX KEY:** 0000704440
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133044880
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CORPORATE DRIVE
- **CITY:** MAHWAH
- **STATE:** NJ
- **ZIP:** 07430
- **BUSINESS PHONE:** 845-469-2042

**MAIL ADDRESS:**
- **STREET 1:** 100 CORPORATE DRIVE
- **CITY:** MAHWAH
- **STATE:** NJ
- **ZIP:** 07430

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REPRO MED SYSTEMS INC
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Adams Thomas Edward<br><sub>(Last) (First) (Middle)</sub><br>C/O KORU MEDICAL SYSTEMS, INC.<br>100 CORPORATE DRIVE<br><sub>(Street)</sub><br>MAHWAH, NJ 07430<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-05-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>KORU Medical Systems, Inc. [ KRMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units<sup>(1)</sup> | <sup>(2)</sup> | 2025-05-12 |  | A<sup>(1)</sup> |  | 32773 |  | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 32773 | $0 | 32773 | D |  |
| Restricted Stock Units<sup>(1)</sup> | <sup>(2)</sup> | 2025-05-12 |  | A<sup>(1)</sup> |  | 32773 |  | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 32773 | $0 | 32773 | D |  |
| Option to buy Common Stock<sup>(1)</sup> | $3.21 | 2025-05-12 |  | A<sup>(1)</sup> |  | 55583 |  | <sup>(5)</sup> | 2035-05-12 | Common Stock | 55583 | $0 | 55583 | D |  |

---

### Footnotes:

(1) Each of the reported securities represent awards made pursuant to the Company's 2024 Omnibus Equity Incentive Plan in connection with the Company's 2025 Long-Term Incentive Program.

(2) Each restricted stock unit represents a contingent right to receive one share of KORU Medical Systems, Inc. (the "Company") upon vesting.

(3) One-fourth will vest on May 12, 2026 and on each first, second and third anniversary thereof or upon an earlier chance in control of the Company.

(4) These restricted stock units will vest based upon achievement of certain performance conditions as of December 31, 2027. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-150% of the amount reported depending on the level of performance achieved, multiplied by between 0.5 to 1.5 times of the earned number of shares. These restricted stock units will vest at 100% of the amount reported upon a change in control of the Company prior to December 31, 2027.

(5) One-fourth will vest on May 12, 2026 and on each first, second and third anniversary thereof.

**Remarks:**
The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.

**Signature:** /s/ Thomas Adams  
**Date:** 2025-08-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**